» Articles » PMID: 37576366

Managing Drug Interactions With Oral Anticancer Treatments

Overview
Date 2023 Aug 14
PMID 37576366
Authors
Affiliations
Soon will be listed here.
Abstract

The use of oral anticancer treatments is widespread and vital to modern cancer treatment. Novel oral chemotherapy and targeted therapy treatments continue to receive US Food and Drug Administration approval every year, making knowledge of these agents a necessity for practitioners working in oncology. Many oral anticancer agents are prone to drug interactions that can contribute to adverse effects and decrease therapy efficacy. Potential drug-drug interactions include (1) interactions with CYP3A4 inhibitors and inducers, (2) interactions related to gastric acid suppression, (3) interactions related to prolongation of the cardiac QT interval, (4) interactions related to anticoagulant medications, and (5) drug-food and drug-herb interactions. Identifying potential drug interactions and appropriately managing them is key to preventing adverse effects and ensuring maximum efficacy while on oral anticancer therapy. Management of adverse effects increases patient compliance, ensures medication safety, and allows patients to remain on therapy. This article discusses the mechanisms of interactions and types of interacting medications. Specific recommendations are discussed.

Citing Articles

Comparing Anticoagulation Strategies for Venous Thromboembolism Associated With Active Cancer: A Systematic Review and Meta-Analysis.

Fujisaki T, Sueta D, Yamamoto E, Buckley C, Sacchi de Camargo Correia G, Aronson J JACC CardioOncol. 2024; 6(1):99-113.

PMID: 38510285 PMC: 10950435. DOI: 10.1016/j.jaccao.2023.10.009.

References
1.
Elbeddini A, To A, Tayefehchamani Y, Wen C . Importance of medication reconciliation in cancer patients. J Pharm Policy Pract. 2021; 14(1):98. PMC: 8628436. DOI: 10.1186/s40545-021-00379-8. View

2.
Nightingale G, Pizzi L, Barlow A, Barlow B, Jacisin T, McGuire M . The prevalence of major drug-drug interactions in older adults with cancer and the role of clinical decision support software. J Geriatr Oncol. 2018; 9(5):526-533. DOI: 10.1016/j.jgo.2018.02.001. View

3.
Keller K, Franquiz M, Duffy A, Trovato J . Drug-drug interactions in patients receiving tyrosine kinase inhibitors. J Oncol Pharm Pract. 2016; 24(2):110-115. DOI: 10.1177/1078155216682311. View

4.
Lam L, Capparelli E, Kurzrock R . Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. Cancer Chemother Pharmacol. 2016; 78(2):427-32. PMC: 4967016. DOI: 10.1007/s00280-016-3087-6. View

5.
Cascorbi I . Drug interactions--principles, examples and clinical consequences. Dtsch Arztebl Int. 2012; 109(33-34):546-55. PMC: 3444856. DOI: 10.3238/arztebl.2012.0546. View